PBLS NASDAQ
Parabilis Medicines, Inc.
1W: -1.3%
1M: -19.8%
3M: -21.7%
YTD: +25.1%
$26.42
+1.39 (+5.55%)
Weekly Expected Move ±11.8%
$19
$22
$24
$27
$30
Credit Risk of going bust: not rated Debt: 1.5% of company value Bonds: none of note held by US funds details ▾
Not rated: insufficient price history.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$6.9M
Congress—
ETF Holdings—
Key Statistics
Market Cap$3.1B
52W Range20-42.49
Volume1,427,693
Avg Volume758,061
Beta5.03
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOMathai Mammen
Employees145
SectorHealthcare
IndustryBiotechnology
IPO Date2026-06-10
Websiteparabilismed.com
30 Acorn Park Dr
Cambridge, MA 02140
US
Cambridge, MA 02140
US
About Parabilis Medicines, Inc.
Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.
Latest News
Brokers Offer Predictions for PBLS Q3 Earnings
Regeneron-backed Parabilis rises ahead of trial data for lead asset
Parabilis Medicines (NASDAQ:PBLS) Reaches New 12-Month Low – Should You Sell?
Parabilis Medicines, Inc. (PBLS) – What Are Analysts Saying About This Stock?
Parabilis Medicines (NASDAQ:PBLS) Stock Price Down 5.2% – Here’s Why
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Tendler Craig | A-Award | 20,294 | $39.36 | 2026-08-22 |
| RA CAPITAL MANAGEMEN | P-Purchase | 47,250 | $29.77 | 2026-07-22 |
| RA CAPITAL MANAGEMEN | P-Purchase | 21,696 | $27.96 | 2026-07-21 |
| RA CAPITAL MANAGEMEN | P-Purchase | 6,504 | $29.17 | 2026-07-21 |
| RA CAPITAL MANAGEMEN | P-Purchase | 37,723 | $30.00 | 2026-07-21 |